Quiescent leukaemic cells account for minimal residual disease in childhood lymphoblastic leukaemia
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Relapses after therapy-induced remissions remain a major challenge in cancer.
1,2 Molecular detection of minimal residual disease (MRD) is valuable in relapse prediction but its cellular basis remains largely unknown. [3] [4] [5] Delineating therapy-resistant cells ( Figure 1a ) might inform new therapeutic strategies. 'Cancer stem cells', defined by xenografting, have been suggested to preferentially evade therapy, but evidence for persistence of phenotypically and functionally distinct cells in patients undergoing treatment is largely lacking.
We investigated the cells responsible for MRD in childhood acute lymphoblastic leukaemia (cALL) (for patient information see Table 1 ), where molecular MRD monitoring has had a practisechanging impact. 6 At presentation, cALLs comprise phenotypically distinct B-cell stages, including ProB-like (CD34 þ CD38 þ CD19 þ ), and cells dubbed 'Stem/B' coexpressing stem (CD34 þ CD38 À /low ) and B-cell (CD19 þ ) markers, seen only in leukaemia and preleukaemia. 7, 8 Although recent studies suggest that cells capable of propagating cALL in xenografts are plastic and extend beyond the Stem/B compartment, 9 its leukaemia-specificity provides a readily trackable biomarker in patients.
We first tracked the fate of leukaemic cells in MRD þ remission samples of three cALL patients who went on to relapse. In patient 1, BCR/ABL1 þ 'Stem/B' cells selectively persisted at remission, when no BCR/ABL1 þ leukaemic cells could be found in other B-cell compartments (Figures 1b and c) . A similar picture emerged from the analysis of ProB-like and Stem/B cells in remission samples in two TEL/AML1 cases (patients 2 and 3; Figure 1d and Supplementary Figure 1A) , suggesting that in patients with relapsed disease, cells within the Stem/B compartment are selectively chemoresistant, sustaining MRD and potentially initiating relapse.
In good-prognosis TEL/AML1 patients who achieved and remain in long-term complete (MRD À ) remission, we observed two behaviours: either Stem/B cells were eliminated with similar kinetics to ProB-like cells (one patient; Supplementary Figure 1B) or more slowly than their ProB counterparts (four patients; Figures 1e and f and Supplementary Figures 1C-E) .
Although variable, as might be expected in a setting where all leukaemic cells are ultimately eliminated, the preferential chemoresistance of Stem/B cells seen in most patients suggests enrichment of cells with specific functional properties within the Stem/B compartment. We speculated that the Stem/B phenotype may represent a surrogate biomarker for quiescence. At diagnosis, Stem/B cells were more quiescent (G 0 ) and less actively cycling (S-M-G 2 ) than leukaemic ProB cells, in all six patients analysed (Figure 1g) . Moreover, in all MRD samples investigated, we found that chemotherapy further selected for a rare but almost exclusively quiescent (G 0 ) population of Stem/B cells ( Figure 1h ).
Our findings (i) suggest that quiescence contributes mechanistically to enhanced chemoresistance within the Stem/B compartment in cALL, a disease arguably derived from B-cell-restricted progenitors, which in contrast to stem cells normally cycle extensively; (ii) highlight the importance and feasibility of tracking rare but distinct cancer cell populations in patients undergoing therapy; and (iii) provide a conceptual framework for reframing the cancer stem cell debate in terms of patient relevance in the form of MRD-sustaining and relapse-initiating cells.
Our results merit comparison with those reported by Wilson et al. 10 These workers concluded that there was no specific cellular basis for therapy resistance in patients with cALL. This conclusion is in line with their view that there is no specific cellular basis for tumour propagation in xenograft models of cALL. 9 The conclusion of the Wilson et al. 10 study is limited by that fact it was solely based on immunophenotypic analysis of patient samples, lacking molecular-based polymerase chain reaction (PCR) or fluorescence in situ hybridization (FISH) analyses affording unambiguous discrimination between leukaemic and non-leukaemic cells. Nevertheless, in line with our own results, Wilson et al. 10 observed that the Stem/B population, still phenotypically detectable in 7/11 MRD þ remission samples, was proportionally spared during therapy relative to other compartments. Wilson et al. 10 chose to interpret these results as reflecting a chemotherapy-induced change Accepted article preview online 22 october 2012; advance online publication, 29 January 2013
Letters to the Editor in cell surface phenotype rather than a selective persistence of a specific cell compartment. We cannot completely rule out that surface phenotypes change in immediate response to chemotherapy, but this does not seem a likely explanation for the selective persistence of distinct immunophenotypes throughout extended remission phases. Regardless and crucially, 
FACS analysis of HSCs, ProB cells and Stem/B cells in a TEL/AML1
þ cALL case at diagnosis, remission and relapse (for patient characteristics and MRD results, see Table 1 ). Percentages of HSCs, Stem/B and ProB cells in total BM MNC are indicated. Populations identified as TEL/AML1 þ by FISH, RQ-PCR and/or immunophenotyping are gated in red (see Supplementary Table 1 our results extend beyond simple cell surface analysis. We link the Stem/B phenotype to the functional property of cell quiescence. This relationship was observed in diagnostic samples that have not been exposed to treatment, thus eliminating any possibility of therapy-induced cell surface modulation. We further show that in all investigated cases therapy enriches for quiescent cells demonstrating the functional relevance of the quiescent state, which is enriched within the Stem/B compartment. This highlights the fact that, although enriched for quiescence, not all Stem/B cells are quiescent. Similarly, not all quiescent cells within the leukaemia are Stem/B cells. It remains to be determined how quiescence and the Stem/B phenotype are regulated and it is plausible that either or both are mutable states influenced by extrinsic cues such as those, resident within the bone marrow or stem cell niche. Such a view would account for stem cell or tumour propagating cell 'plasticity' reported in cALL. 9 Despite limitations of our study with cases in which we determined leukaemic cells by aberrant phenotype in follow-up samples or could not detect residual ALL cells in samples with evidence for molecular MRD, our data clearly suggest that persistent Stem/B cells in follow-up samples carry increased risk of relapse.
The need to eliminate highly quiescent cALL cells provides a plausible explanation for the requirement for prolonged (2-3 years) maintenance therapy to achieve durable clinical remissions in cALL. 11, 12 It also provides a plausible explanation for cALL cases, in which the relapse clone resembles the presentation leukaemic clone up to 8 years between diagnosis and relapse. 13 One possible approach to eradicate resistant and quiescent ALL cells would be to induce cell cycling. Proof of principle of such an approach has been demonstrated. Normal haematopoietic stem cells (HSCs) are usually resistant to treatment with antiproliferative drugs such as 5-fluoro-uracil. However, after treatment with interferon-a to induce cell cycle entry of HSCs, these cells were efficiently killed with 5-fluoro-uracil. 14 In a similar vein, recent xenograft studies have shown that dormant acute myeloid leukaemia (AML) cells become susceptible to chemotherapy after cell cycle-inducing treatment with granulocyte colonystimulating factor. 15 Therefore, further exploration of combinations of cycle-inducing agents with established chemotherapies might prove a profitable avenue for successful elimination of otherwise resistant cALL cells. Letters to the Editor
